Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

Image
Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

BERKELEY HEIGHTS -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) scheduled two sessions on its TNX-801 horsepox-based vaccine platform at World Vaccine Congress Europe in Amsterdam on Oct. 19-21, 2026. The company still lists the program as pre-IND, with a Phase 1 study not expected before 2027.

Tonix announced the sessions on Oct. 15, 2026, four days before the congress opened. Three of the four named speakers are Tonix employees. The fourth comes from the Kenya Medical Research Institute (KEMRI).

Tonix fields two of three speakers in a vectored-vaccine working group

The working group, "Vectored Vaccine Platforms: From Design to Improving Efficacy," was set for Oct. 20 at 11:30 a.m. CEST. Tonix leads it. Sina Bavari, Ph.D., Executive Vice President, Infectious Disease at the Tonix Research and Development Center (RDC), and Gabriella Worwa, DVM, Ph.D., RDC Study Director, represent the company. Matilu Mwau, Senior Principal Clinical Research Scientist and Professor of Infectious Diseases at KEMRI, is the third presenter.

A day later, on Oct. 21 at 1:15 p.m. CEST, Farooq Nasar, Ph.D., MPH, Director of Virology at the RDC, was scheduled to give an oral presentation titled "TNX-801 Vaccine Platform Safety and Efficacy." It sits in the congress's Emerging & Infectious Diseases category.

Tonix did not disclose what data the presentation will contain.

TNX-801 is the only non-marketed Tonix program described as pre-clinical

The release names four non-marketed programs. TNX-102 SL is in Phase 2 studies for major depressive disorder and acute stress disorder/acute stress reaction. TNX-4800 (Lyme disease) and TNX-1500 (kidney transplant rejection) are described as Phase 2-ready. TNX-801 is the only one of the four in pre-clinical development, so the "safety and efficacy" session covers a candidate that has not entered human trials.

Tonix describes TNX-801 as a live, attenuated, minimally replicative vaccine platform based on horsepox virus. It is aimed at mpox, smallpox and other emerging infectious diseases. The company's marketed products are TONMYA, Zembrace SymTouch and Tosymra, all in CNS indications, so the vaccine program sits outside its commercial portfolio.

Tonix expects TNX-801 to enter a Phase 1 study in 2027, pending FDA clearance of an Investigational New Drug (IND) application.

Published by:
fairsonline_team
Products
Target market(s)
News Type